Fecal calprotectin in inflammatory bowel diseases: update and perspectives
- 1 January 2017
- journal article
- review article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 55 (4), 474-483
- https://doi.org/10.1515/cclm-2016-0522
Abstract
Inflammatory bowel diseases (IBDs) are chronic diseases that result from the inflammation of the intestinal wall, suspected in any patient presenting with intestinal symptoms. Until recently, the diagnosis was mainly based on both clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive, and inexpensive biological assay is mandatory not only in diagnosis but also in evolutionary and therapeutic monitoring. To date, the fecal calprotectin is the most documented in this perspective. This marker allows the discrimination between functional and organic bowel processes with good performance. The determination of the fecal calprotectin level contributes to the evaluation of the degree of disease activity and to monitoring of therapeutic response.Keywords
This publication has 66 references indexed in Scilit:
- Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary careScandinavian Journal of Gastroenterology, 2013
- Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndromeAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)Gut, 2011
- Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levelsWorld Journal of Gastroenterology, 2011
- Inflammatory Bowel Disease Confers a Lower Risk of Colorectal Cancer to Females Than to MalesGastroenterology, 2010
- Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective studyEuropean Journal of Gastroenterology & Hepatology, 2010
- Prospective evaluation of faecal neutrophil‐derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectinAlimentary Pharmacology & Therapeutics, 2007
- Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?Gut, 2005
- Fecal α1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileumEuropean Journal of Gastroenterology & Hepatology, 2003
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisThe New England Journal of Medicine, 1987